Aptose Biosciences Inc. , a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming Biotech ShowcaseTM 2017 Conference on Tuesday, January 10th at 9:00 a.m. PST in San Francisco, CA. The audio webcast will be archived shortly after the live event and will be available through the Aptose website at www.aptose.com .
Category: Medicine
Cellectar Biosciences to Present at the 9th Annual Biotech Showcase
Cellectar Biosciences, Inc. , an oncology-focused, clinical stage biotechnology company, announces today that President and CEO, Jim Caruso will present at the Biotech Showcase in San Francisco on January 11, 2017 at 10:00 AM PT in Room 2 . “We look forward to discussing the continued advancement of our lead PDC program, CLR 131, as well as providing relevant updates on our other product candidates and corporate performance,” said Mr. Caruso.
OncoMed Announces Year-End Cash Balance and 2017 Outlook
OncoMed Pharmaceuticals Inc. , a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today pre-announced its 2016 year-end cash balance and reviewed key anticipated events for 2017. OncoMed ended 2016 with approximately $184.6 million in cash.
Tiny Boston Biotech Pieris Nabs $570 Million+ Cancer Deal With French Powerhouse Servier
Pieris and Servier, an independent international pharmaceutical company headquartered in France with annual sales of more than EUR4 billion, to jointly pursue several bispecific therapeutic programs including Pieris’ proprietary dual checkpoint inhibitor PRS-332 Alliance includes four additional bispecific programs and may be expanded to a total of eight immuno-oncology programs ; Pieris has option to co-develop and retain US rights for 4 of these programs, including PRS-332 Pieris to receive EUR30 million upfront, up to EUR324 million in success-based payments for PRS-332, up to EUR193 million in success-based payments for each of the other programs and up to double-digit royalties Pieris will host an investor conference call on Thursday, January 5, 2017 at 8:30 AM to discuss the collaboration : PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its … (more)
Skin Cancer Breakthrough 2017: Melanoma Spread Reduced By Up To 90% With New Man-Made Compound
Skin cancer is the most common form of cancer is the world, and although melanoma is a more rare form, it is also the most deadly . New research from Michigan State University may soon change this.
The Latest at CES: Wrap text message like a present for $120
LeEco CEO Jia Yueting, left, and Nick Sampson, Faraday Future’s senior vice president of product research & development, shake hands after unveiling the FF91 electric car at CES International Tuesday, Jan. 3, 2017, in Las Vegas. The Smartcane is on display during CES Unveiled before CES International, Tuesday, Jan. 3, 2017, in Las Vegas.
Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer
Dr. Lockshin is a life science executive with an extensive background in cross-functional R&D management, with a particular focus on drug discovery, preclinical and clinical development. Dr. Lockshin is an inventor on numerous patents related to small-molecule therapeutics, biomaterials and optical biosensors.
East/West CEO Conference to Feature Prominent CEOs and Industry Leaders on January 7th & 8th
Join Deborah Dunsire,CEO, Southern Cross Biotech Consulting;Tom Heyman,CEO, Janssen Pharmaceutica;Charlotte Hubbert,Partner, Bill & Melinda Gates Foundation;Emil Kakkis,CEO & President, Ultragenyx;Mathai Mammen,SVP Research, Merck;Geoff McDonough,President & CEO, Sobi;Susan Molineaux,President & CEO, Calithera;Paris Panayiotopoulos,President & CEO, ARIAD;Rob Perez,Founder and Chairman, Life Science Cares;David Pyott,Former CEO, Allergan;Paul Stoffels,CSO, Johnson & Johnson;Henri Termeer, former CEO,Genzyme;J.
Researchers develop first non-human primate X-SCID models using genome editing techniques
Researchers affiliated with the K awasaki IN novation G ateway at SKYFRONT, have successfully generated the first ever non-human primate X-SCID models by using two genome editing techniques. The findings were published in Cell Stem Cell, July 2016.
Amgen Hikes Dividend By 15%. Is It A Buy, Sell, Or Hold?
Early in the year, I said that Amgen’s dividend growth is likely to slow down . Specifically, this was my reasoning: Amgen has expanded its payout ratio from 7% in 2011 to 40% now.
Demonetization as Indian tragedy: Modi silent on specifics of black money : The Canadian National Newspaper
For several months, we, at The Canadian, have been documenting complaints against Dr. Jerry Tenenbaum which subvert the integrity of OHIP specifically and Canada’s public healthcare system in general. On 30 December 2016, the Toronto Star further documented how the province’s 12 top-billing doctors – who received payments of between $2 million and $7 million in one year – are overcharging the Ontario Health Insurance Plan.
Neogen Corporation (NEOG) Position Decreased by Rehmann Capital Advisory Group
Rehmann Capital Advisory Group reduced its position in shares of Neogen Corporation by 0.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission . The fund owned 3,882 shares of the company’s stock after selling 17 shares during the period.
First Robotic Surgery Training Centre in Asia Where More than 600 Surgeons trained in 6 Year
GURGAON, NCR DELHI, INDIA, December 31, 2016 / EINPresswire.com / — World Laparoscopy Hospital , Gurgaon is one of the most popular laparoscopic and robotic surgery training institute of the World. World Laparoscopy Hospital is the only institute in Asia which gives structured da Vinci robotic surgery training in structured manner and after this Hands On training surgeons, urologists and gynaecologists become eligible for Fellowship of International College of Robotic Surgeons.
CES 2017: From new smart TVs to sleep tech, here’s what to expect
The eyes of the tech world will be firmly fixed on Las Vegas when the Consumer Electronics Show kicks off next week. CES 2017 also marks the event’s 50th anniversary and news.com.au ‘s technology editor Matthew Dunn will be there to take in all the action, and there’s plenty to look forward to.
Press release distribution, EDGAR filing, XBRL, regulatory filings
After many years serving in d… )–Opus Bank announced today that it completed on December 23, 2016 the securitization of approximately $509 million of its multifamily loans th… )–ALS and AD bioinformatics reports confirm GM6’s role as regulator of disease-relevant pathways.
Pluristem Therapeutics And New York Blood Center To Collaborate In…
Pluristem Therapeutics And New York Blood Center To Collaborate In Evaluating PLX-R18 As An Adjuvant Therapy To Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD Prior research has suggested that PLX-R18 helps cord blood cells to engraft more rapidly and effectively Grant of $900,000 from Israel-U.S. Binational Industrial Research and Development Foundation to fund the research Constitutes a 3rd potential hematologic indication for PLX-R18 HAIFA, Israel, Dec. 27, 2016 — Pluristem Therapeutics Inc. , a leading developer of placenta-based cell therapy products, today announced that it will collaborate with the New York Blood Center on preclinical studies of its Placental eXpanded -R18 cells to enhance the efficacy of umbilical cord blood transplantation.
Press release distribution, EDGAR filing, XBRL, regulatory filings
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of Alexion Pharmaceuticals, Inc. who purchased shares between February 10, 2014 … SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of TerraVia Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of TerraVia Holdings, Inc. who purchased shares between August 8,… DPLO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Diplomat Pharmacy, Inc. and a Lead Plaintiff Deadline of January 9, 2017 )–The Law Offices of Vincent Wong … (more)
Press release distribution, EDGAR filing, XBRL, regulatory filings
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of Alexion Pharmaceuticals, Inc. who purchased shares between February 10, 2014 … SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of TerraVia Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of TerraVia Holdings, Inc. who purchased shares between August 8,… DPLO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Diplomat Pharmacy, Inc. and a Lead Plaintiff Deadline of January 9, 2017 )–The Law Offices of Vincent Wong … (more)
Continue Reading…
Africa has changed remarkably, and for the better, since I first worked as a young doctor in Angola some 20 years ago. But no change has been more obvious than the way the continent has adopted mobile technology.
Continue Reading…
Africa has changed remarkably, and for the better, since I first worked as a young doctor in Angola some 20 years ago. But no change has been more obvious than the way the continent has adopted mobile technology.
World Laparoscopy Hospital Says That Surgeons and Gynecologists Can…
Here is news that may interest surgeons. They can get trained in laparoscopy because the Delhi-based World Laparoscopy Hospital is offering a four-week integrated dual-degree postgraduate Diploma program in Laparoscopic Surgery that will earn the candidates D.MAS or Diploma in Minimal Access Surgery and F.MAS or Fellowship in Minimal Access Surgery.
Health Care Companies Showing Good Defensive Potential
Among U.S. companies, health care companies offer good defensive-investing opportunities. Such companies, including Johnson & Johnson , Biogen Inc. and VCA Inc. , generally had strong financial strength and gross margins.
Artificial kidney called ‘holy grail’
A video emerged on Tuesday night of Michael Floyd’s DUI arrest in Arizona from last week.
Neogen Corp. (NEOG) Posts Earnings Results, Beats Expectations By $0.02 EPS
Neogen Corp. released its earnings results on Wednesday. The company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02.
Neogen Corp. (NEOG) Posts Earnings Results, Beats Expectations By $0.02 EPS
Neogen Corp. released its earnings results on Wednesday. The company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02.
Bristol-Myers Squibb and Calithera Biosciences Announce Clinical…
Bristol-Myers Squibb Company and Calithera Biosciences , Inc. , a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma . CB-839 is an orally administered glutaminase inhibitor currently in Phase 1/2 clinical studies.
Replacing missing gut bacteria could help treat children with rare autoimmune disease
Defects in the body’s regulatory T cells cause inflammation and autoimmune disease by altering the type of bacteria living in the gut, researchers from The University of Texas Health Science Center at Houston have discovered. The study, “Resetting microbiota by Lactobacillus reuteri inhibits T reg deficiency-induced autoimmunity via adenosine A2A receptors,” which will be published online December 19 in The Journal of Experimental Medicine, suggests that replacing the missing gut bacteria, or restoring a key metabolite called inosine, could help treat children with a rare and often fatal autoimmune disease called IPEX syndrome.
Shionogi And Purdue Pharma L.P. Establish Alliance For Joint U.S. Commercialization Of Naldemedine
OSAKA, Japan & STAMFORD, Conn.– — Shionogi & Co., Ltd. , a drug-discovery based pharmaceutical company dedicated to developing medicines that protect the health and well-being of patients, and its wholly-owned U.S. subsidiary, Shionogi Inc. , and Purdue Pharma L.P. , a privately-held pharmaceutical company founded by physicians over 60 years ago, distinguished by its pioneering research, products and medical programs directed toward alleviating pain, today announced the establishment of an alliance for the joint U.S. launch and commercialization of SymproicA .
MicroRNA Differences Across the Course of Aging Correlate with Life Span
Become a SENS Patron by pledging a monthly donation to the SENS Research Foundation in support of rejuvenation research programs. Pledge before the end of the 2016 and we will match the next year of your gifts.
Merck Wins Record $2.5 Billion Patent Verdict Against Gilead
Gilead Sciences Inc. was told by a federal jury to pay $2.54 billion to Merck & Co. for using a patented invention as the basis for its blockbuster drugs for the potentially deadly liver disease hepatitis C — the biggest patent-infringement verdict in U.S. history.
Greenwood, SC
GwdToday is looking for a breaking news reporter to join our team. This person will be responding to emergency situations such as fires, accidents and crime scenes.
Oncolytics Biotech Inc. Announces 2016 Year-End Results
“Through this process, and with the help of our expanding senior team, we thoughtfully and deliberately put in place a plan that initially contemplates combinations with chemotherapy for late-stage clinical development, but will expand to include targeted immunotherapies over the longer term as we look to leverage the role of the immune system in patient treatment. In the coming months we will specifically define our first registration pathway.